Ocata Therapeutics Inc. (NASDAQ:OCAT), based in Marlborough, Massachusetts, formerly known as Advanced Cell Technology Inc., or ACT, have announced the publication of data in the… Read More »Ocata Therapeutics Inc., announces publication of data on the generation of corneal endothelial cells from human pluripotent stem cells
An application to conduct gene-editing research in human embryos, by the Francis Crick Institute in London, has been approved by the UK’s regulatory body, HFEA.… Read More »UK’s Human Fertilisation and Embryo Authority (HFEA) approves license for gene-editing in human embryos
Research, conducted across 42 ophthalmology centres in the United States, has reported that point-of-care measurement of hemoglobin A1c (HbA1c), combined with personalized diabetes risk assessment… Read More »Research suggests that the impact of individualized patient assessment and diabetes-risk education on glycemic control may not be sufficiently effective
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the February 8th, 2016 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »February 8th, 2016: “EURETINA-Brief”© Issue No. 126
Spark Therapeutics (NASDAQ:ONCE), a gene therapy company based in Philadelphia, USA, has announced a three year vision to expand the company’s gene therapy portfolio and… Read More »Spark Therapeutics announces plans to have 10 gene therapy clinical programs in place by 2018, including up to three ophthalmic indications
Results from a Phase II study to evaluate the safety and efficacy of a micro- injectable formulation of triamcinolone for the treatment of macular edema… Read More »Phase II clinical trial results for micro-injection of triamcinolone in treatment of macular edema (following non-infectious uveitis) reaches primary endpoint
Research conducted by an international consortium of ophthalmic genetic specialists has reported the identification of a further three loci believed to contribute to the pathology… Read More »Genomic meta-analysis across patient DNA of European ancestry uncovers three additional genetic loci behind glaucoma
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the January 18th, 2016 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »January 18th, 2016: “EURETINA-Brief”© Issue No. 125
The recently developed CRISPR gene editing technology is currently generating significant interest in the biomedical community, not least of all due to its low cost,… Read More »CRISPR gene editing technology continues to create significant commercial interest including applications to ophthalmology
Bayer AG (Xetra: BAYN), Leverkusen, Germany and CRISPR Therapeutics AG, Basel, Switzerland have announced the creation of a 50/50 joint venture “to discover, develop and… Read More »Bayer AG and CRISPR Therapeutics AG announce joint venture targeting blindness, heart disease and blood disorders.